Theodoros Tsakiridis
Overview
Explore the profile of Theodoros Tsakiridis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1517
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Di Pastena F, Pond G, Tsakiridis E, Gouveia A, Ahmadi E, Biziotis O, et al.
Radiat Oncol
. 2024 Nov;
19(1):155.
PMID: 39511611
Introduction: Growth differentiation factor 15 (GDF15) is a cytokine of the TGFβ family. Here, we analyzed GDF15 levels in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who participated...
2.
Sigurdson S, Al Salman K, Mesci A, Dayes I, Quan K, Goldberg M, et al.
Can Urol Assoc J
. 2024 Oct;
19(2):17-24.
PMID: 39418495
Introduction: This study aimed to assess the detection rate of prostate cancer recurrence by prostate-specific member antigen-positron emission tomography/computed tomography (PSMA-PET/CT) with F-DCFPyL in patients with residual disease or biochemical...
3.
Viani G, Gouveia A, Louie A, Arcidiacono F, Simone 2nd C, Tsakiridis T, et al.
Radiother Oncol
. 2024 Jul;
201:110439.
PMID: 39032835
Introduction: To evaluate the feasibility, efficacy and safety of stereotactic ablative radiotherapy (SABR) to the primary tumor and lymph nodes in patients with locally advanced non-small cell lung cancer (LA-NSCLC)...
4.
Moraes F, Gouveia A, Marta G, da Silva M, Hamamura A, Tsakiridis T, et al.
Int J Radiat Oncol Biol Phys
. 2024 Jan;
119(5):1403-1412.
PMID: 38244875
Purpose: The efficacy and safety of stereotactic body radiation therapy (SBRT) for patients with nonspine bone metastases remains in question. A systematic review and meta-analysis were performed to evaluate SBRT...
5.
Ahmadi E, Wang S, Gouran-Savadkoohi M, Douvi G, Isfahanian N, Tsakiridis N, et al.
Int J Mol Sci
. 2023 Nov;
24(22).
PMID: 38003213
Metabolic dysregulation is an early event in carcinogenesis. Here, we examined the expression of enzymes involved in de novo lipogenesis (ATP-citrate lyase: ACLY), glucose uptake (Glucose Transporter 1: GLUT1), and...
6.
Hu H, Anagnostopoulos G, Gouran-Savadkoohi M, Dayes I, Ishkanian A, Hallock A, et al.
Prostate
. 2023 Oct;
84(2):193-202.
PMID: 37880911
Background: Advantages of using stereotactic body radiation therapy to treat prostate cancer include short treatment times, decreased costs, and limited toxicity. Randomized trial outcomes comparing 5-fraction stereotactic body radiation therapy...
7.
Desjardins E, Wu J, Lavoie D, Ahmadi E, Townsend L, Morrow M, et al.
Cell Rep Med
. 2023 Sep;
4(9):101193.
PMID: 37729871
Increased liver de novo lipogenesis (DNL) is a hallmark of nonalcoholic steatohepatitis (NASH). A key enzyme controlling DNL upregulated in NASH is ATP citrate lyase (ACLY). In mice, inhibition of...
8.
Ali A, Mekhaeil B, Biziotis O, Tsakiridis E, Ahmadi E, Wu J, et al.
Commun Biol
. 2023 Sep;
6(1):919.
PMID: 37684337
Radiotherapy is a non-invasive standard treatment for prostate cancer (PC). However, PC develops radio-resistance, highlighting a need for agents to improve radiotherapy response. Canagliflozin, an inhibitor of sodium-glucose co-transporter-2, is...
9.
Beers C, Pond G, Wright J, Tsakiridis T, Okawara G, Swaminath A
Front Oncol
. 2023 Sep;
13:1210945.
PMID: 37681028
Purpose: Fluoro-2-deoxyglucose positron-emission tomography (FDG-PET/CT) is now considered a standard investigation for the staging of new cases of stage III NSCLC. However, there is not published level 3 evidence demonstrating...
10.
Biziotis O, Tsakiridis E, Ali A, Ahmadi E, Wu J, Wang S, et al.
Mol Oncol
. 2023 Aug;
17(11):2235-2256.
PMID: 37584455
Non-small cell lung cancer (NSCLC) has a poor prognosis, and effective therapeutic strategies are lacking. The diabetes drug canagliflozin inhibits NSCLC cell proliferation and the mammalian target of rapamycin (mTOR)...